Third quarter 2018 results

Posted on Nov 13, 2018

Oslo (Norway), 13 November 2018 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announces its interim third quarter 2018 result. Please find enclosed the report and presentation. The fully underwritten rights issue of NOK 360 million completed in October 2018 provides PCI Biotech with the funds needed for the pivotal fimaCHEM study, […]

Invitation to third quarter 2018 presentation

Posted on Nov 6, 2018

Oslo, Norway, 06 November 2018 – PCI Biotech invites to a presentation of the company’s third quarter 2018 report on Tuesday 13 November 2018 at Oslo Cancer Cluster Innovation Park. Time: Tuesday November 13, 08:30am – 09:30am CET (local time). Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation Park, Ullernchausséen 64, […]

Capital increase registered and listing of new shares

Posted on Oct 24, 2018

Oslo, Norway, 24 October 2018. Reference is made to the previous announcements by PCI Biotech Holding ASA (“PCI Biotech” or the “Company”) in respect of the issuance of 170,000 new shares following exercise of employee share options in the Company. The  share capital increase resolved by the Board of Directors following the share option exercise […]